ArticleThe Journal of experimental medicine2019
Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML.
Open access · hybridAbstract read
In one paragraph
Article in The Journal of experimental medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed
6.4field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 120 citations in OpenAlex.
- Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2021Trial
- Aberrant Expression ofBioMed research international · 2019Trial
- Trisomy 8 alters chromatin conformations and activates Y chromosome genes in stem cells to drive a pre-leukemic state.Oncogene · 2026Article
- Multiomic analysis of clonal development reveals new regulators of leukemic cell growth.Genes & development · 2026Article
- Review
- Review
- Observation of PICALM::MLLT10-rearrangement and coincidental EZH2 mutations in a patient with acute myeloid leukemia: A case report and review of the literature.BJC reports · 2025Article
- Gene regulatory complexes: their role and regulation across normal and malignant hematopoiesis.Experimental hematology · 2025Review
- The epigenetic revolution in hematology: from benchside breakthroughs to clinical transformations.Clinical and experimental medicine · 2025Review
- Epigenetic dysregulation in acute myeloid leukemia.Seminars in hematology · 2025Review
- Pharmacokinetics, metabolism, and excretion of [Cancer chemotherapy and pharmacology · 2025Article
- Targeting chromatin modifying complexes in acute myeloid leukemia.Stem cells translational medicine · 2025Review
- A dual role for PSIP1/LEDGF in T cell acute lymphoblastic leukemia.Science advances · 2024Article
- Molecular Features and Treatment Paradigms of Acute Myeloid Leukemia.Biomedicines · 2024Review
- Contributions of transcriptional noise to leukaemia evolution: KAT2A as a case-study.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2024Review
- Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2.European journal of medicinal chemistry · 2024Article
- FLT3 tyrosine kinase inhibition modulates PRC2 and promotes differentiation in acute myeloid leukemia.Leukemia · 2024Article
- Article
- Review
- Preleukemic single-cell landscapes reveal mutation-specific mechanisms and gene programs predictive of AML patient outcomes.Cell genomics · 2023Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on byDual roles of2019
Authors and funding
24 authors at 10 institutions in 3 countries.
Faisal BasheerWellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.
George GiotopoulosWellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.ORCID 0000-0003-1390-6592
Eshwar MeduriWellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.
Haiyang YunWellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.
Milena MazanWellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.
Daniel SascaWellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.
Paolo GallipoliWellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.ORCID 0000-0001-7254-2253
Ludovica MarandoWellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.
Malgorzata GozdeckaWellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.
Ryan AsbyWellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.ORCID 0000-0001-5077-3798
Olivia SheppardWellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.
Monika DudekWellcome Trust Sanger Institute, Hinxton, UK.
Lars BullingerCharité University Hospital, Berlin, Germany.
Hartmut DöhnerDepartment of Internal Medicine III, University of Ulm, Ulm, Germany.ORCID 0000-0003-2116-5536
Richard DillonDepartment of Medical and Molecular Genetics, Kings College School of Medicine, UK.
Sylvie FreemanDepartment of Clinical Immunology, University of Birmingham Medical School, Edgbaston, Birmingham, UK.
Oliver OttmannDepartment of Haematology, University of Cardiff, Cardiff, UK.
Alan BurnettIsle of Arran, UK.
Nigel RussellDepartment of Haematology, University of Nottingham, Nottingham, UK.
Elli PapaemmanuilDepartments of Epidemiology and Biostatistics and Cancer Biology, the Center for Molecular Oncology and the Center for Hematologic Malignancies, Memorial Sloan-Kettering Cancer Center, New York, NY.
Robert HillsNuffield Department of Population Health, University of Oxford, Oxford, UK.
Peter CampbellWellcome Trust Sanger Institute, Hinxton, UK.
George S VassiliouWellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK.ORCID 0000-0003-4337-8022
Brian J P HuntlyWellcome Trust-Medical Research Council Cambridge Stem Cell Institute, Cambridge, UK bjph2@cam.ac.uk.ORCID 0000-0003-0312-161X
Wellcome/MRC Cambridge Stem Cell Institute · GBWellcome Sanger Institute · GBCardiff University · GBCharité - Universitätsmedizin Berlin · DEKing's College School · GBMemorial Sloan Kettering Cancer Center · USUniversität Ulm · DEUniversity of Birmingham · GBUniversity of Nottingham · GBUniversity of Oxford · GB
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MCancer Research UK 23015Cancer Research UK 25508Cancer Research UK C18680/A25508Department of HealthMedical Research Council MC_PC_12009Medical Research Council MR/R009708/1NCI NIH HHS P30 CA008748Wellcome TrustWellcome Trust 097922/Z/11/ZWellcome Trust 100140Wellcome Trust 109967/Z/15/Z
Abstract
Epigenetic regulators, such as EZH2, are frequently mutated in cancer, and loss-of-function
Indexed as
Disease ProgressionLoss of Function MutationAnimalsBone Marrow CellsBone Marrow TransplantationCell Line, TumorCohort StudiesDisease Models, AnimalEnhancer of Zeste Homolog 2 ProteinGene FrequencyHistonesHumansLeukemia, Myeloid, AcuteMiceMice, Inbred C57BLPrognosisEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanEzh2 protein, mouseHistones
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.